Physician profile
Sunil Agrawal
NPI 1093953747
$40,222.00
in general payments reported to CMS, 2019-2025
47 companies · $3,318 in 2025
The $3,318 reported for 2025 was more than what 92% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,323 · 2020: $5,591 · 2021: $10K · 2022: $12K · 2023: $2,313 · 2024: $5,138 · 2025: $3,318.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,161 · Consulting Fee: $2,850 · Travel and Lodging: $657 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,160.89 |
| Consulting Fee | $2,850.00 |
| Travel and Lodging | $656.53 |
| Education | $101.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $13,357.15 | 2019-2024 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $6,760.11 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $4,636.97 | 2019-2025 | Jynarque |
| Calliditas Therapeutics US INC. | $3,155.19 | 2022-2025 | Tarpeyo |
| Vantive US Healthcare LLC | $1,543.31 | 2025 | Renal - Acute, Renal - Pd |
| Amgen INC. | $1,358.63 | 2019-2025 | Krystexxa, Tavneos, Parsabiv |
| Opko Pharmaceuticals, LLC | $902.08 | 2019-2025 | Rayaldee |
| Travere Therapeutics, INC. | $898.52 | 2022-2025 | |
| Vifor Pharma, INC. | $838.16 | 2019-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $754.38 | 2019-2025 | Velphoro, Velphoro |
| Mallinckrodt Hospital Products INC. | $717.27 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $491.24 | 2023-2025 | |
| Horizon Therapeutics Plc | $446.75 | 2021-2023 | Krystexxa |
| Daiichi Sankyo INC. | $372.81 | 2019-2022 | |
| Aurinia Pharma U.S., INC. | $368.37 | 2021-2024 | Lupkynis |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Agrawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.